RT Book, Section A1 Wellstein, Anton A1 Atkins, Michael B. A2 Brunton, Laurence L. A2 Knollmann, Björn C. SR Print(0) ID 1193242789 T1 Antibodies, CAR T Cells, and Proteins to Treat Cancer T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264258079 LK accessanesthesiology.mhmedical.com/content.aspx?aid=1193242789 RD 2024/03/29 AB A Note on Treatment RegimensCancer treatment regimens change to reflect continuous advances in basic and clinical science: new drugs, both small molecules and biologicals; improved methods of targeting and timing of drug delivery; agents with altered pharmacokinetic properties and selectivities; the use of rational multidrug combinations; and greater knowledge of the basic cell biology of tumorigenesis, metastasis, and immune function, among other advances. As a consequence, this chapter presents only a few detailed treatment regimens; rather, we refer the reader to the web-based resources of the U.S. FDA (drugs@fda) and the NCCN (National Comprehensive Cancer Network). Table 71–1 provides two examples of therapeutic regimens that illustrate the complexity of current cancer drug therapy.